Journal Article10.1182/BLOOD.V124.21.3358.3358
Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System
Rowan Kuiper,Martin H. van Vliet,Erik H. van Beers,Annemiek Broijl,George Mulligan,Hervé Avet-Loiseau,Walter M Gregory,Gareth J. Morgan,Hartmut Goldschmidt,Henk M. Lokhorst,Mark van Duin,Pieter Sonneveld +11 more
2
TL;DR: ISS, cytogenetics and gene expression profiling (GEP) were combined to find novel risk stratifications in a discovery/validation setting and showed that the ISS-GEP combinations consistently rank at the top.
read more
About: This article is published in Blood. The article was published on 06 Dec 2014.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14).
TL;DR: The patient was Multiple Myeloma International Staging System (ISS) stage III (R-ISS stage II) at diagnosis, but with the presence of high risk GEP, and there was a strong rationale to consider the addition of the BCL2inhibitor venetoclax and the patient now met criteria for compassionate access.
Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/<scp>UK</scp> Myeloma Society Good Practice Paper
Martin Kaiser,Guy Pratt,Ceri Bygrave,Kristian M. Bowles,Simon Stern,Matthew Jenner +5 more
TL;DR: This Good Practice Paper provides recommendations for the diagnosis and initial management of transplant-eligible high-risk myeloma patients and provides recommendations for treatment on the basis of recent prospective clinical trial evidence.
References
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14).
TL;DR: The patient was Multiple Myeloma International Staging System (ISS) stage III (R-ISS stage II) at diagnosis, but with the presence of high risk GEP, and there was a strong rationale to consider the addition of the BCL2inhibitor venetoclax and the patient now met criteria for compassionate access.